Your session is about to expire
← Back to Search
Glucagon-like peptide-1 receptor agonist
Semaglutide + Lifestyle Counseling for Heart Failure
Phase 2
Recruiting
Led By Barry Borlaug, MD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
NYHA Class II-IV
NT-proBNP levels and echocardiography criteria based on BMI at screening
Must not have
Recent cardiovascular events or planned revascularization procedures
Presence of amyloid cardiomyopathy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 12 months
Awards & highlights
Summary
This trial will test if weight loss can help improve heart function in obese people with heart failure.
Who is the study for?
This trial is for adults with obesity-related heart issues (HFpEF) who have a BMI of 30 or higher, experience certain types of heart failure symptoms, and haven't been hospitalized for heart failure in the last month. People can't join if they've had bariatric surgery, used GLP-1 receptor agonists recently, have specific health risks like pancreatitis or severe psychiatric disorders, are pregnant or not using effective contraception, plan major surgery that affects walking ability during the trial period.
What is being tested?
The study tests whether an aggressive weight loss intervention combined with Semaglutide improves symptoms in patients with HFpEF compared to a placebo group. Participants will also receive counseling on healthy lifestyle changes as part of the treatment process.
What are the potential side effects?
Semaglutide may cause side effects such as digestive problems (nausea and vomiting), potential inflammation of organs like the pancreas (pancreatitis), allergic reactions if sensitive to ingredients, and possibly affect blood sugar levels.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have moderate to severe heart condition symptoms.
Select...
My heart function tests are within the required range for my body size.
Select...
I was hospitalized for worsening heart failure in the last year and had an echocardiogram.
Select...
I have not been hospitalized for heart failure in the last 30 days.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have had recent heart problems or plan to undergo a procedure to improve blood flow.
Select...
I have heart disease caused by amyloid buildup.
Select...
My main breathing issue is caused by a specific condition.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline, 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 12 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Pulmonary Capillary Wedge Pressure (PCWP)
Secondary study objectives
Body fat mass
Change in Quality of Life (QOL) as assessed by Kansas City Cardiomyopathy Questionnaire (KCCQ)
Left Atrial (LA) reservoir strain
+14 moreTrial Design
2Treatment groups
Active Control
Placebo Group
Group I: Semaglutide TreatmentActive Control2 Interventions
Subjects will receive Semaglutide once weekly in addition to counselling on healthy lifestyle intervention
Group II: Placebo TreatmentPlacebo Group2 Interventions
Subjects will receive matching placebo once weekly in addition to counselling on healthy lifestyle intervention
Find a Location
Who is running the clinical trial?
Mayo ClinicLead Sponsor
3,298 Previous Clinical Trials
3,958,364 Total Patients Enrolled
75 Trials studying Heart Failure
1,021,955 Patients Enrolled for Heart Failure
United States Department of DefenseFED
891 Previous Clinical Trials
332,397 Total Patients Enrolled
1 Trials studying Heart Failure
90 Patients Enrolled for Heart Failure
Barry Borlaug, MDPrincipal InvestigatorMayo Clinic
9 Previous Clinical Trials
1,378 Total Patients Enrolled
6 Trials studying Heart Failure
998 Patients Enrolled for Heart Failure
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have moderate to severe heart condition symptoms.I have had recent heart problems or plan to undergo a procedure to improve blood flow.My heart function tests are within the required range for my body size.I have heart disease caused by amyloid buildup.My main breathing issue is caused by a specific condition.I have had bariatric surgery or have obesity-related health issues.I was hospitalized for worsening heart failure in the last year and had an echocardiogram.I have not been hospitalized for heart failure in the last 30 days.You have a body mass index (BMI) of 30 or higher.
Research Study Groups:
This trial has the following groups:- Group 1: Semaglutide Treatment
- Group 2: Placebo Treatment
Awards:
This trial has 2 awards, including:- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger